US2778772A - Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system - Google Patents

Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system Download PDF

Info

Publication number
US2778772A
US2778772A US318761A US31876152A US2778772A US 2778772 A US2778772 A US 2778772A US 318761 A US318761 A US 318761A US 31876152 A US31876152 A US 31876152A US 2778772 A US2778772 A US 2778772A
Authority
US
United States
Prior art keywords
stimulation
dimethyl
compositions
dimethyl phenyl
sympathetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US318761A
Inventor
Chen Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parke Davis and Co LLC
Original Assignee
Parke Davis and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis and Co LLC filed Critical Parke Davis and Co LLC
Priority to US318761A priority Critical patent/US2778772A/en
Priority to US619925A priority patent/US2991227A/en
Application granted granted Critical
Publication of US2778772A publication Critical patent/US2778772A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • This invention relates to compositions useful for stimulating the autonomic ganglia containing as the effective ingredient 1,1-dimethyl-4-phenylpiperazinium iodide.
  • this previously known compound Chemical Abstracts 29, 4013 (1935)
  • This newly discovered property makes it possible to use the compound for the laboratory determination of the effectiveness of potential ganglionic blocking agents.
  • the autonomic ganglion system is composed of the sympathetic ganglia and the parasympathetic ganglia. Stimulation of the sympatthetic ganglia causes release of an epinephrine-like substance by the postganglionic fibers while stimulation of the parasympathetic ganglia causes release of acetyl choline by both the preand post-ganglionic fibers.
  • compositions of the present invention are prepared by dissolving l,l-dimethyl-4-phenylpiperazinium iodide in water, isotonic saline or isotonic glucose and sterilizing the resulting solutions by heat or by Zeitz filtration. It will also be appreciated that the compositions can be prepared under aseptic conditions using sterile ingredients.
  • the solutions which are the most useful in the detection of ganglionic disorders are those containing 0.5 to 5 milligrams of the quaternary halide compound in each milliliter of the solution. These solutions are administered by the parenteral route and preferably intravenously.
  • compositions of the invention can be demonstrated on the sympathetic ganglia using pentobarbitalized cats and measuring the contraction of the nictating membrane caused by injection of a measured quantity of the composition.
  • 200 micrograms per kg. of 1,1-dimethyl-4-phenylpiperazinium iodide give the same degree of response as 5 micrograms per kg. of
  • the physiological effect on the parasympathetic ganglia can be demonstrated by the increase in bladder pressure of female dogs under pentobarbital anesthesia following intravenous injection of a solution of 1,1-dimethyl-4- phenylpiperazinium iodide. In this test it only required 10 to 20 micrograms per kg. of 1,1-dimethyl-4-phenylpiperazinium iodide in order to bring about a change in bladder pressure and it was possible to block this pressure change completely by the administration of 10 milligrams per kg. of triethylammonium chloride.
  • compositions of the invention exert a stimulating effect upon the ganglion-like material of the adrenal medulla and are therefore useful in determining the ability of the adrenal medulla to produce epinephrine.
  • compositions of the invention are relatively nontoxic.
  • the LDso of 1,1-dimethyl-4-phenylpiperazinium iodide is 27.5 milligrams per kg. in mice given intramuscularly and l milligram per kg. in rabbits intravenously.
  • Example 1 milligrams of 1,1-dimethyl-4-phenylpiperazinium iodide is dissolved in 100 ml. of an isotonic salt solution containing 850 milligrams of sodium chloride. 1 ml. portions of the solution are placed in 2 m1. ampoules and the ampoules sealed. The ampouled material is sterilized by heating the ampoules in an autoclave for twenty minutes at C. The material in the ampoules is assayed for its effect upon the sympathetic and parasympathetic ganglia by the methods mentioned above. Each ampoule should contain approximately one milligram per milliliter of 1,1-dimethyl-4-phenylpiperazinium iodide.
  • Example 2 50 mg. of 1,1-dimethyl-4-phenylpiperazinium iodide is dissolved in 100 ml. of distilled water. 1 ml. portions of the solution are placed in glass ampoules and the ampoules sealed. The ampouled material is sterilized by heating in a steam autoclave for fifteen minutes at fifteen pounds pressure steam. The material in the ampoules is assayed by the methods mentioned in Example 1. Each ampoule should contain 0.5 milligram of 1,1-dimethyl-4- phenylpiperazinium iodide.
  • a composition for the stimulation of the sympathetic and parasympathetic ganglia comprising an aqueous solution containing 0.5 to 5 milligrams per milliliter of 1,1- dimethyl-4-phenylpiperazinium iodide.
  • a composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous, isotonic, saline solution containing 1 milligram per milliliter of l,l-dimethyl-4-phenylpiperazinium iodide.
  • a composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous solution containing 0.5 milligram per milliliter of 1,1-dimethy1-4-phenylpiperazinium iodide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent Graham Chen, Detroit, Mich., assignor to Parke, Davis & Company, a corporation of Michigan Application November 4, 1952, Serial No. 318,761
No Drawing.
4 Claims.
This invention relates to compositions useful for stimulating the autonomic ganglia containing as the effective ingredient 1,1-dimethyl-4-phenylpiperazinium iodide. I have discovered that this previously known compound, Chemical Abstracts 29, 4013 (1935), has the physiological property of exerting a stimulating effect on both the sympathetic and parasympathetic ganglia. This newly discovered property makes it possible to use the compound for the laboratory determination of the effectiveness of potential ganglionic blocking agents.
The autonomic ganglion system is composed of the sympathetic ganglia and the parasympathetic ganglia. Stimulation of the sympatthetic ganglia causes release of an epinephrine-like substance by the postganglionic fibers while stimulation of the parasympathetic ganglia causes release of acetyl choline by both the preand post-ganglionic fibers.
In many clinical conditions the normal functions of the autonomic ganglion system are impaired or stimulated and it is of great value to the practitioner to be able to ascertain whether this is due to the ganglion system itself or some other cause. In order to test the functioning of the autonomic ganglion system it is necessary to utilize some substance which will disturb in a controllable fashion the normal operation of the sympathetic and parasympathetic ganglia. It is known that nicotine is capable of stimulating both the sympathetic and parasympathetic ganglia. However, nicotine is a relatively weak stimulant and is unsatisfactory and dangerous to use clinically due to the depressive, toxic and paralyzing effects which it produces. Epinephrine and norepinephrine exert a stimulating effect upon the effector cells but they do not act on either the sympathetic or parasympathetic ganglia.
The compositions of the present invention are prepared by dissolving l,l-dimethyl-4-phenylpiperazinium iodide in water, isotonic saline or isotonic glucose and sterilizing the resulting solutions by heat or by Zeitz filtration. It will also be appreciated that the compositions can be prepared under aseptic conditions using sterile ingredients. The solutions which are the most useful in the detection of ganglionic disorders are those containing 0.5 to 5 milligrams of the quaternary halide compound in each milliliter of the solution. These solutions are administered by the parenteral route and preferably intravenously.
The physiological effect of the compositions of the invention can be demonstrated on the sympathetic ganglia using pentobarbitalized cats and measuring the contraction of the nictating membrane caused by injection of a measured quantity of the composition. When tested in accordance with this method 200 micrograms per kg. of 1,1-dimethyl-4-phenylpiperazinium iodide give the same degree of response as 5 micrograms per kg. of
'" ice (iiii'iiizvhfiiii: tiiiiiiig'l'i the areas; cells: The errataof the l,l-dimethyl-4-phenylpiperazinium iodide are completely blocked by the administration of 10 milligrams perkg. of the ganglionic blocking agent, triethylammoniurn chloride. Under these same conditions the stimulating effect of epinephrine was not blocked because it does not act upon the ganglia.
The physiological effect on the parasympathetic ganglia can be demonstrated by the increase in bladder pressure of female dogs under pentobarbital anesthesia following intravenous injection of a solution of 1,1-dimethyl-4- phenylpiperazinium iodide. In this test it only required 10 to 20 micrograms per kg. of 1,1-dimethyl-4-phenylpiperazinium iodide in order to bring about a change in bladder pressure and it was possible to block this pressure change completely by the administration of 10 milligrams per kg. of triethylammonium chloride.
The compositions of the invention exert a stimulating effect upon the ganglion-like material of the adrenal medulla and are therefore useful in determining the ability of the adrenal medulla to produce epinephrine. In utilizing the compositions for this purpose one injects a measured quantity of the ganglionic stimulating agent and measures the amount of stimulation obtained with and without a ganglionic blocking agent. The difference in the response obtained under these two conditions is a measure of the adrenal medullas ability to produce epinephrine.
The compositions of the invention are relatively nontoxic. For example, the LDso of 1,1-dimethyl-4-phenylpiperazinium iodide is 27.5 milligrams per kg. in mice given intramuscularly and l milligram per kg. in rabbits intravenously.
The invention is illustrated by the following examples:
Example 1 milligrams of 1,1-dimethyl-4-phenylpiperazinium iodide is dissolved in 100 ml. of an isotonic salt solution containing 850 milligrams of sodium chloride. 1 ml. portions of the solution are placed in 2 m1. ampoules and the ampoules sealed. The ampouled material is sterilized by heating the ampoules in an autoclave for twenty minutes at C. The material in the ampoules is assayed for its effect upon the sympathetic and parasympathetic ganglia by the methods mentioned above. Each ampoule should contain approximately one milligram per milliliter of 1,1-dimethyl-4-phenylpiperazinium iodide.
Example 2 50 mg. of 1,1-dimethyl-4-phenylpiperazinium iodide is dissolved in 100 ml. of distilled water. 1 ml. portions of the solution are placed in glass ampoules and the ampoules sealed. The ampouled material is sterilized by heating in a steam autoclave for fifteen minutes at fifteen pounds pressure steam. The material in the ampoules is assayed by the methods mentioned in Example 1. Each ampoule should contain 0.5 milligram of 1,1-dimethyl-4- phenylpiperazinium iodide.
What I claim is:
1. A composition for the stimulation of the sympathetic and parasympathetic ganglia comprising an aqueous solution containing 0.5 to 5 milligrams per milliliter of 1,1- dimethyl-4-phenylpiperazinium iodide.
2. A composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous, isotonic, saline solution containing 1 milligram per milliliter of l,l-dimethyl-4-phenylpiperazinium iodide.
3. A composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous solution containing 0.5 milligram per milliliter of 1,1-dimethy1-4-phenylpiperazinium iodide.
4. The method of testing the efiectiveness of ganglionic blocking agents, comprising administering to an experimental animal- 1,1-dimethyl-4-phenylpiperazinium iodide for the laboratory determination of the effectiveness of potential ganglionic blocking agents.
References Cited in the file of this patent Howard: Modern Drug Encyclopedia, fifth ed. Drug Publications 1952, New York, pages 113-114.

Claims (1)

1. A COMPOSITION FOR THE STIMULATION OF THE SYMPATHETIC AND PARASYMPATHETIC GANGLIA COMPRISING AN AQUEOUS SOLUTION CONTAINING 0.5 TO 5 MILLIGRAMS PER MILLILITER OF 1,1DIMETHYL-4-PHENLPIPERAZINIUM IODIDE.
US318761A 1952-11-04 1952-11-04 Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system Expired - Lifetime US2778772A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US318761A US2778772A (en) 1952-11-04 1952-11-04 Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
US619925A US2991227A (en) 1952-11-04 1956-11-02 Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US318761A US2778772A (en) 1952-11-04 1952-11-04 Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system

Publications (1)

Publication Number Publication Date
US2778772A true US2778772A (en) 1957-01-22

Family

ID=23239484

Family Applications (1)

Application Number Title Priority Date Filing Date
US318761A Expired - Lifetime US2778772A (en) 1952-11-04 1952-11-04 Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system

Country Status (1)

Country Link
US (1) US2778772A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2991227A (en) * 1952-11-04 1961-07-04 Parke Davis & Co Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system
US20040132737A1 (en) * 2001-03-23 2004-07-08 Yvon Cormier Nicotinic receptor agonists for the treatment of inflammatory diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20080221085A1 (en) * 2004-07-15 2008-09-11 Universite Laval Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2991227A (en) * 1952-11-04 1961-07-04 Parke Davis & Co Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system
US20040132737A1 (en) * 2001-03-23 2004-07-08 Yvon Cormier Nicotinic receptor agonists for the treatment of inflammatory diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20070249622A1 (en) * 2001-03-23 2007-10-25 Universite Laval Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases
US7601720B2 (en) 2001-03-23 2009-10-13 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8377936B2 (en) 2001-03-23 2013-02-19 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8551983B2 (en) 2002-03-25 2013-10-08 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20080221085A1 (en) * 2004-07-15 2008-09-11 Universite Laval Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases

Similar Documents

Publication Publication Date Title
Todd et al. Duration of ischemia influences the development and resolution of ischemic brain edema.
Kirby et al. Pruritic effect of bile salts
Jamerson et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin
US3035974A (en) Compositions and method for the parenteral administration of thyroxine
US2778772A (en) Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
Laburn et al. Pyrogen and prostaglandin fever in the rabbit—II: Effects of noradrenaline depletion and adrenergic receptor blockade
Fisch et al. Enhancement of potassium-induced atrioventricular block by toxic doses of digitalis drugs
Mitchell et al. Is prostaglandin E the neural mediator of the febrile response? The case against a proven obligatory role.
Wilkins et al. Potassium and the pathogenesis of cerebral arterial spasm in dog and man
Vogt Cortical lipids of the normal and denervated suprarenal gland under conditions of stress
Salzberg et al. Blood Volumes in Normal and Burned Dogs: A Comparative Study with Radioactive Phosphorus Tagged Red Cells and T-1824 Dye1, 2
US2991227A (en) Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system
Woolley et al. Differentiation between receptors for serotonin and tryptamine by means of the exquisite specificity of antimetabolites
BECKER et al. Acute effects of oral phosphate on visual function in multiple sclerosis
Rosenbaum et al. Efficacy of antibodies to adhesion molecules, CDlla or CD18, in rabbit models of uveitis
Barnett et al. Cyclic AMP and cyclic GMP in canine peripheral lung: regulation in vivo
Bennett et al. The passage of proteins from the vascular system into joints and certain other body cavities
Metcalf et al. The effect of various amine-depleting drugs on the fever response exhibited by rabbits to bacterial or leucocyte pyrogen.
Hayes et al. Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease
Willies et al. The effect of sodium salicylate on dibutyryl cyclic AMP fever in the conscious rabbit
Burks et al. Neurotransmitter mediation of morphine hypothermia in rats
US3639626A (en) Suppressing the activity of plasmin in humans and animals with trans-4-(aminomethyl)-cyclohexane - 1 - carboxylic acid
US3824313A (en) Topical opthalmic composition and methods of use
Wong et al. Intraocular injection of prostaglandins: Modification of response to circulating bacterial endotoxin
US2850428A (en) Partially depolymerized hyaluronic acid as a spreading and lipemiaclearing agent